Table 5 Clinical trials of long-acting erythropoiesis-stimulating agents in peritoneal dialysis patients in Japan
From: 2015 Japanese Society for Dialysis Therapy: Guidelines for Renal Anemia in Chronic Kidney Disease
| Â | Journal title | Number of patients | Length of study (weeks) | Target Hb levels (g/dL) | Hb levels at end of treatment (g/dL) | Serious adverse events | Other side effects (hypertension, etc.) |
|---|---|---|---|---|---|---|---|
DA | Ther Apher Dial [63] | 72 | 28 | Target range: 11–12 | New: 10.6 | Death: 2 (unrelated) | Hypertension: 22 |
Maintained: 10–13 | Switched: 10.5 | ||||||
DA | Clin Exp Nephrol [64] | 96 | 28 | 11–13 | 11.9±1.2 | Death: 0 | Hypertension: 22 |
CERA | Jpn Pharmacol Ther [65] | 63 | 48 | 10–12 | SC: 10.88±0.70 | Death: 0 | Hypertension: 2 |
IV: 10.78±0.93 | |||||||
CERA | Ren Fail [66] | 83 | 48 | 11–13 | 11.8±1.5 | Death: 1 (unrelated) | Hypertension (not provided) |